Literature DB >> 30507270

Fatigue at enrollment predicts EDSS worsening in the New York State Multiple Sclerosis Consortium.

Caila B Vaughn1, Katelyn S Kavak2, Michael G Dwyer3, Aisha Bushra2, Muhammad Nadeem2, Diane L Cookfair4, Murali Ramanathan5, Ralph Hb Benedict6, Robert Zivadinov7, Andrew Goodman8, Lauren Krupp9, Robert W Motl10, Bianca Weinstock-Guttman1.   

Abstract

BACKGROUND: Fatigue is one of the most common and distressing symptoms among persons with multiple sclerosis (pwMS).
OBJECTIVE: The aim of this study is to evaluate fatigue as a predictor for disease worsening among pwMS.
METHODS: In this retrospective cohort study of New York State MS Consortium (NYSMSC) registry, MS patients reporting moderate-to-severe fatigue at study enrollment (n = 2714) were frequency matched to less-fatigued subjects (n = 2714) on age, baseline Kurtzke Expanded Disability Status Scale (EDSS), disease duration, and MS phenotype. Change from baseline patient-reported outcomes (PROs), as measured by LIFEware™, categorized participants into two groups: those with stable/improved outcomes and those who worsened. In a subgroup of patients with longitudinal data (n = 1951), sustained EDSS worsening was analyzed using Cox proportional hazards modeling to explore the effect of fatigue.
RESULTS: The median survival time from study enrollment to sustained EDSS worsening was 8.7 years (CI: 7.2-10.1). Participants who reported fatigue at baseline were more likely to experience sustained EDSS worsening during follow-up (HR: 1.4, 95% CI: 1.2-1.7). Patients who were fatigued at baseline were also more likely to report worsening psychosocial limitations (all ps ⩽ 0.01).
CONCLUSION: In addition to being a common symptom of MS, severe fatigue was a significant predictor for EDSS worsening in the NYSMSC.

Entities:  

Keywords:  EDSS worsening; Fatigue; patient-reported outcomes; progression

Mesh:

Year:  2018        PMID: 30507270     DOI: 10.1177/1352458518816619

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  9 in total

1.  The impairment of the functional system and fatigue at the onset of the disease predict reaching disability milestones in relapsing-remitting multiple sclerosis differently in female and male patients.

Authors:  Alina Ivaniuk; Yuliia Solodovnikova; Tetiana Marusich; Anatoliy Son
Journal:  Acta Neurol Belg       Date:  2020-09-30       Impact factor: 2.396

2.  Predicting Long-term Disability in Multiple Sclerosis: A Narrative Review of Current Evidence and Future Directions.

Authors:  Bianca Weinstock-Guttman; Maria Pia Sormani; Pavle Repovic
Journal:  Int J MS Care       Date:  2022-10-05

3.  The Multiple Sclerosis Surveillance Registry: A Novel Interactive Database Within the Veterans Health Administration.

Authors:  Mitchell T Wallin; Ruth Whitham; Heidi Maloni; Shan Jin; Jonathan Duckart; Jodie Haselkorn; William J Culpepper
Journal:  Fed Pract       Date:  2020-04

4.  Cognitive Functioning in Patients with Pediatric-Onset Multiple Sclerosis, an Updated Review and Future Focus.

Authors:  Joy B Parrish; Emily Fields
Journal:  Children (Basel)       Date:  2019-02-04

Review 5.  Dimethyl Fumarate in the Treatment of Relapsing-Remitting Multiple Sclerosis: Patient Reported Outcomes and Perspectives.

Authors:  Osman Ozel; Caila B Vaughn; Svetlana P Eckert; Dejan Jakimovski; Alexis A Lizarraga; Bianca Weinstock-Guttman
Journal:  Patient Relat Outcome Meas       Date:  2019-12-11

6.  Cognitive Fatigue Is Associated with Altered Functional Connectivity in Interoceptive and Reward Pathways in Multiple Sclerosis.

Authors:  Michelle H Chen; John DeLuca; Helen M Genova; Bing Yao; Glenn R Wylie
Journal:  Diagnostics (Basel)       Date:  2020-11-10

7.  Confirmed disability progression provides limited predictive information regarding future disease progression in multiple sclerosis.

Authors:  Brian C Healy; Bonnie I Glanz; Elyse Swallow; James Signorovitch; Kaitlin Hagan; Diego Silva; Corey Pelletier; Tanuja Chitnis; Howard Weiner
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-04-11

Review 8.  Multiple sclerosis-related fatigue lacks a unified definition: A narrative review.

Authors:  Iman Adibi; Mehdi Sanayei; Farinaz Tabibian; Neda Ramezani; Ahmad Pourmohammadi; Kiarash Azimzadeh
Journal:  J Res Med Sci       Date:  2022-03-17       Impact factor: 1.852

9.  Natalizumab wearing-off symptoms: effect of extend interval dosing during Sars-CoV-2 pandemic.

Authors:  Giuseppe Magro; Stefania Barone; Federico Tosto; Antonio De Martino; Domenico Santange Lo; Lucia Manzo; Angelo Pascarella; Pietro Bruno; Marilisa Pasquale; Antonio Gambardella; Paola Valentino
Journal:  J Neurol       Date:  2022-10-13       Impact factor: 6.682

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.